StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) PT Raised to $88 at Cantor Fitzgerald
October 26, 2018 10:49 AM
Cantor Fitzgerald analyst Alethia Young ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
Gilead Sciences (GILD) Reports 96-Wk Data from Phase 3 Study of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for HIV-1 Treatment in Adults New to HIV Therapy
October 30, 2018 7:17 AM
